Chargement en cours...
Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
Cancer immunotherapy was selected as the Breakthrough of the Year 2013 by the editors of Science, in part because of the successful treatment of refractory hematological malignancies with adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells. Effective treatment of B cell leukemia...
Enregistré dans:
| Publié dans: | BioDrugs |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer International Publishing
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4544486/ https://ncbi.nlm.nih.gov/pubmed/25859858 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-015-0122-9 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|